Literature DB >> 9788828

Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition.

G Vescovo1, L Dalla Libera, F Serafini, C Leprotti, L Facchin, M Volterrani, C Ceconi, G B Ambrosio.   

Abstract

BACKGROUND: In congestive heart failure, fatigue-resistant, oxidative, slow type I fibers are decreased in leg skeletal muscle, contributing to exercise capacity (EC) limitation. The mechanisms by which ACE inhibitors and AII antagonists improve EC is still unclear. We tested the hypothesis that improvement in EC is related to changes in skeletal muscle composition toward type I fibers. METHODS AND
RESULTS: Eight patients with congestive heart failure, NYHA classes I through IV, were treated for 6 months with enalapril (E) 20 mg/d, and another 8 with losartan (L) 50 mg/d. EC was assessed with maximal cardiopulmonary exercise testing at baseline and after treatment. Myosin heavy chain (MHC) composition of the gastrocnemius was studied after electrophoretic separation of slow MHC1, fast oxidative MHC2a, and fast glycolytic MHC2b isoforms from needle microbiopsies obtained at baseline and after 6 months. EC improved in both groups. Peak V(O2) increased from 21.0+/-4.7 to 27.6+/-4.3 mL . kg-1 . min -1 (P=0.011) in the L group and from 17.5+/-5.0 to 25.0+/-5.5 mL . kg-1 . min -1 (P=0.014) in the E group. Similarly, ventilatory threshold changed from 15.0+/-4.0 to 19.9+/-4.9 mL (P=0. 049) with L and from 12.0+/-1.9 to 15.4+/-3.5 mL (P=0.039) with E. MCH1 increased from 61.2+/-11.2% to 75.4+/-7.6% with L (P=0.012) and from 60.6+/-13.1% to 80.1+/-10.9% (P=0.006) with E. Similarly, MHC2a decreased from 21.20+/-9.5% to 12.9+/-4.4% (P=0.05) with L and from 19.9+/-7.8% to 11.8+/-7.9% (P=0.06) with E. MHC2b changed from 17. 5+/-6.5% to 11.7+/-5.2% (P=0.07) with L and from 19.5+/-6.4% to 8. 1+/-4.6% (P=0.0015) with E. There was a significant correlation between net changes in MHC1 and absolute changes in peak V(O2) (r2=0.29, P=0.029) and a trend to significance for MHC2a and 2b.
CONCLUSIONS: Six months' treatment with L and with E produces an improvement in EC of similar magnitude. These changes are accompanied by a reshift of MHCs of leg skeletal muscle toward the slow, more fatigue-resistant isoforms. Magnitude of MHC1 changes correlates with the net peak V(O2) gain, which suggests that improved EC may be caused by favorable biochemical changes occurring in the skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788828     DOI: 10.1161/01.cir.98.17.1742

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

Review 1.  Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure.

Authors:  Holly R Middlekauff
Journal:  Circ Heart Fail       Date:  2010-07       Impact factor: 8.790

2.  Oxidative phenotype protects myofibers from pathological insults induced by chronic heart failure in mice.

Authors:  Ping Li; Richard E Waters; Shelley I Redfern; Mei Zhang; Lan Mao; Brian H Annex; Zhen Yan
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 3.  Ace inhibitors as a therapy for sarcopenia - evidence and possible mechanisms.

Authors:  D Sumukadas; M D Witham; A D Struthers; M E T McMurdo
Journal:  J Nutr Health Aging       Date:  2008 Aug-Sep       Impact factor: 4.075

Review 4.  Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia.

Authors:  G Onder; C Della Vedova; F Landi
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

Review 5.  Validated treatments and therapeutic perspectives regarding physical activities.

Authors:  Y Rolland; F Pillard
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

6.  Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes.

Authors:  G Vescovo; M Volterrani; R Zennaro; M Sandri; C Ceconi; R Lorusso; R Ferrari; G B Ambrosio; L Dalla Libera
Journal:  Heart       Date:  2000-10       Impact factor: 5.994

Review 7.  Losartan: a review of its use, with special focus on elderly patients.

Authors:  K L Simpson; K J McClellan
Journal:  Drugs Aging       Date:  2000-03       Impact factor: 3.923

Review 8.  Metabolic and structural impairment of skeletal muscle in heart failure.

Authors:  Cynthia Zizola; P Christian Schulze
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

Review 9.  Exercise training in chronic heart failure: improving skeletal muscle O2 transport and utilization.

Authors:  Daniel M Hirai; Timothy I Musch; David C Poole
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-08-28       Impact factor: 4.733

10.  Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial.

Authors:  Deepa Sumukadas; Miles D Witham; Allan D Struthers; Marion E T McMurdo
Journal:  CMAJ       Date:  2007-10-09       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.